Cargando…

Mosquirix™ RTS, S/AS01 Vaccine Development, Immunogenicity, and Efficacy

Malaria is a parasitic infection caused by bites from Plasmodium falciparum (P. falciparum)-infected mosquitoes with a present scale of symptoms ranging from moderate fever to neurological disorders. P. falciparum is the most lethal of the five strains of malaria, and is a major case of morbidity an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nadeem, Aroosa Younis, Shehzad, Adeeb, Islam, Salman Ul, Al-Suhaimi, Ebtesam A., Lee, Young Sup
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143879/ https://www.ncbi.nlm.nih.gov/pubmed/35632469 http://dx.doi.org/10.3390/vaccines10050713

Ejemplares similares

RTS,S/AS01 malaria vaccine (Mosquirix(®)): a profile of its use
por: Syed, Yahiya Y.
Publicado: (2022)

Impact of high human genetic diversity in Africa on immunogenicity and efficacy of RTS,S/AS01 vaccine
por: Tukwasibwe, Stephen, et al.
Publicado: (2023)

The thermostability of the RTS,S/AS01 malaria vaccine can be increased by co-lyophilizing RTS,S and AS01
por: Fortpied, Juliette, et al.
Publicado: (2020)

In-silico analysis of potent Mosquirix vaccine adjuvant leads
por: Onyango, Okello Harrison, et al.
Publicado: (2023)

Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immunity
por: AL-Suhaimi, Ebtesam A, et al.
Publicado: (2013)

Musings on malaria morbidity and mortality after the new Mosquirix(®) vaccine
por: Sackey, Adziri H
Publicado: (2019)

Lirioresinol B dimethyl ether inhibits NF-κB and COX-2 and activates IκBα expression in CCl(4)-induced hepatic fibrosis
por: Shehzad, Adeeb, et al.
Publicado: (2020)

Environmental modifiers of RTS,S/AS01 malaria vaccine efficacy in Lilongwe, Malawi
por: Bell, Griffin J., et al.
Publicado: (2020)

Re: Musings on malaria morbidity and mortality after the new Mosquirix(®) vaccine
por: Asante, Kwaku Poku, et al.
Publicado: (2019)

Acceptance, availability, and feasibility of RTS, S/AS01 malaria vaccine: A review
por: Mumtaz, Hassan, et al.
Publicado: (2023)

A Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01(E) and RTS,S/AS01(B) Delayed Fractional Dose Regimens in Malaria-Naive Adults
por: Moon, James E, et al.
Publicado: (2020)

Prostaglandin E(2) Reverses Curcumin-Induced Inhibition of Survival Signal Pathways in Human Colorectal Carcinoma (HCT-15) Cell Lines
por: Shehzad, Adeeb, et al.
Publicado: (2014)

Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial
por: White, Michael T, et al.
Publicado: (2015)

The Future of the RTS,S/AS01 Malaria Vaccine: An Alternative Development Plan
por: Gosling, Roly, et al.
Publicado: (2016)

A Randomized Trial Assessing the Safety and Immunogenicity of AS01 and AS02 Adjuvanted RTS,S Malaria Vaccine Candidates in Children in Gabon
por: Lell, Bertrand, et al.
Publicado: (2009)

PRPF overexpression induces drug resistance through actin cytoskeleton rearrangement and epithelial-mesenchymal transition
por: Islam, Salman Ul, et al.
Publicado: (2017)

Methanolic Extract of Artemia salina Eggs and Various Fractions in Different Solvents Contain Potent Compounds That Decrease Cell Viability of Colon and Skin Cancer Cell Lines and Show Antibacterial Activity against Pseudomonas aeruginosa
por: Islam, Salman Ul, et al.
Publicado: (2019)

Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders
por: Islam, Salman Ul, et al.
Publicado: (2020)

Potential effect modification of RTS,S/AS01 malaria vaccine efficacy by household socio-economic status
por: Gyaase, Stephaney, et al.
Publicado: (2021)

Towards Eradication of Malaria: Is the WHO’s RTS,S/AS01 Vaccination Effective Enough?
por: Arora, Navneet, et al.
Publicado: (2021)

Should India be considering deployment of the first malaria vaccine RTS, S/AS01?
por: Rahi, Manju, et al.
Publicado: (2022)

RTS,S/AS01 Malaria Vaccine - The Next Step for a Developing Country
por: ZEHRA, ASMAT, et al.
Publicado: (2022)

Implementation strategies for the introduction of the RTS,S/AS01 (RTS,S) malaria vaccine in countries with areas of highly seasonal transmission: workshop meeting report
por: Merle, Corinne S.
Publicado: (2023)

CXCR3(+) T Follicular Helper Cells Induced by Co-Administration of RTS,S/AS01B and Viral-Vectored Vaccines Are Associated With Reduced Immunogenicity and Efficacy Against Malaria
por: Bowyer, Georgina, et al.
Publicado: (2018)

Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S/AS01E malaria vaccine efficacy
por: Dobaño, Carlota, et al.
Publicado: (2019)

Impacts of Ecology, Parasite Antigenic Variation, and Human Genetics on RTS,S/AS01e Malaria Vaccine Efficacy
por: Bell, Griffin J., et al.
Publicado: (2021)

RTS,S malaria vaccine efficacy and immunogenicity during Plasmodium falciparum challenge is associated with HLA genotype
por: Nielsen, C.M., et al.
Publicado: (2018)

Simulated Impact of RTS,S/AS01 Vaccination Programs in the Context of Changing Malaria Transmission
por: Brooks, Alan, et al.
Publicado: (2012)

T Cell Responses to the RTS,S/AS01(E) and RTS,S/AS02(D) Malaria Candidate Vaccines Administered According to Different Schedules to Ghanaian Children
por: Ansong, Daniel, et al.
Publicado: (2011)

Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on Genotypes of P. falciparum in Adults Participating in a Malaria Vaccine Clinical Trial
por: Waitumbi, John N., et al.
Publicado: (2009)

Evaluation of RTS,S/AS02A and RTS,S/AS01B in Adults in a High Malaria Transmission Area
por: Polhemus, Mark E., et al.
Publicado: (2009)

Ad35.CS.01 - RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults
por: Ockenhouse, Christian F., et al.
Publicado: (2015)

Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa
por: Otieno, Lucas, et al.
Publicado: (2020)

The Anti-Circumsporozoite Antibody Response of Children to Seasonal Vaccination With the RTS,S/AS01(E) Malaria Vaccine( )
por: Sagara, Issaka, et al.
Publicado: (2021)

Cost of introducing and delivering RTS,S/AS01 malaria vaccine within the malaria vaccine implementation program
por: Baral, Ranju, et al.
Publicado: (2023)

Randomized Controlled Trial of RTS,S/AS02(D) and RTS,S/AS01(E) Malaria Candidate Vaccines Given According to Different Schedules in Ghanaian Children
por: Owusu-Agyei, Seth, et al.
Publicado: (2009)

Avidity of Anti-Circumsporozoite Antibodies following Vaccination with RTS,S/AS01(E) in Young Children
por: Olotu, Ally, et al.
Publicado: (2014)

A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine
por: White, Michael T, et al.
Publicado: (2014)

Long-term immunogenicity and immune memory response to the hepatitis B antigen in the RTS,S/AS01(E) malaria vaccine in African children: a randomized trial
por: Valéa, Innocent, et al.
Publicado: (2020)

Induction of Plasmodium falciparum-Specific CD4(+) T Cells and Memory B Cells in Gabonese Children Vaccinated with RTS,S/AS01(E) and RTS,S/AS02(D)
por: Agnandji, Selidji T., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_cfkss43oi5a6o62vsvbs4b2ivp